title: Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.
abstract: OBJECTIVE
  To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.
  
  
  METHODS
  A 50-year-old male with chronic hepatitis C received treatment with alfa-interferon and ribavirin for 52 weeks. He developed immune-mediated diabetes mellitus with low C-peptide and positive antiglutamic acid decarboxylase antibody after completion of therapy. The hepatitis C infection was eradicated, but he continued to be diabetic requiring insulin therapy during the follow-up.
  
  
  CONCLUSIONS
  This report shows thatimmune-mediateddiabetes mellitus can occur as a late complication of alfa-interferon therapy.
authors.affiliation: Department of Gastroenterology, The Royal Hospital, Muscat, Oman. jagan01@omantel.net.om
authors.forename: Sivasankara
authors.initials: S
authors.lastname: Radhakrishnan
authors.forename: Amal
authors.initials: A
authors.lastname: Upadhyay
authors.forename: Nihar
authors.initials: N
authors.lastname: Mohan
authors.forename: Anjan
authors.initials: A
authors.lastname: Dhar
authors.forename: Harbhajan Kaur
authors.initials: HK
authors.lastname: Walia
authors.forename: Ghazi
authors.initials: G
authors.lastname: Zubaidi
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015551:Autoimmunity; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009850:Oman; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin